Related Experiment Video
Updated: Aug 17, 2026
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Medium and long-term growth in children receiving intranasal beclomethasone dipropionate: a clinical experience
Lyndon E Mansfield1, Catherine P Mendoza
1El Paso Institute for Medical Research and Development, Tex 79902, USA.
Insights
Long-term use of intranasal beclomethasone dipropionate (BDP) in children with allergic rhinitis did not decrease height growth. Careful monitoring is recommended, as the treatment remains effective for managing symptoms.
Area of Science:
- Pediatric Endocrinology
- Allergy and Immunology
- Pharmacology
Background:
- Previous short-term studies indicated a potential decrease in growth velocity with intranasal beclomethasone dipropionate (BDP).
- Children with allergic rhinitis often require prolonged treatment, necessitating an evaluation of long-term effects.
Purpose of the Study:
- To assess the long-term impact of intranasal BDP on height growth in pediatric patients with allergic rhinitis.
Main Methods:
- Retrospective chart review of children under 10 years old initiated on intranasal BDP for allergic rhinitis.
- Comparison of height percentiles before treatment and at final follow-up visits after an average of 36 months of therapy.
Main Results:
- Sixty children (mean age 70 months) were included in the study.
- The mean height percentile increased from 44.6 pre-therapy to 52.2 at the final visit.
- No association was found between long-term intranasal BDP use and decreased height growth.
Conclusions:
- Long-term intranasal BDP treatment for allergic rhinitis in children is not linked to diminished height growth.
- Observed outcomes may be influenced by variations in long-term compliance compared to short-term studies.
- Intranasal BDP remains an effective treatment, though careful, biannual height monitoring is advised for all pediatric patients.
Background:
A 12-month controlled pediatric study of intranasal beclomethasone dipropionate (BDP) reported a 0.9 cm decrease in annual height growth velocity. Since children with allergic rhinitis may be treated for years, this report evaluates long-term height growth effects.
Methods:
We reviewed the clinical charts of children with allergic rhinitis who were treated for the first time with intranasal BDP and were less than 10 years of age at initiation. Height was determined by stadiometry before intranasal corticosteroid therapy and compared with height at a final visit.
Results:
Sixty children aged 24 to 117 months (mean age, 70 months) were treated for an average of 36 months. The pretherapy height percentile was 44.6, which increased to the 52.2 percentile at the final visit.
Conclusions:
Long-term clinical use of intranasal BDP in children was not associated with decreased height growth. This outcome may reflect decreased long-term compliance compared with a short-term study. However, the treatment remained effective. Some children may be at special risk. Careful height measurements are recommended every 6 months.
More Related Videos
07:28Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
07:04Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
Published on: September 16, 2018
Related Concept Videos
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:23Inhaled Medications